Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China

Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China

Nov 16, 2020
|
staff reporter

NEW YORK – Myriad Genetics on Monday announced plans to expand access to its myChoice CDx in Europe and China.

In China, Myriad signed a development and commercial agreement with Burning Rock Biotech to use its myChoice homologous recombination deficiency (HRD) test in Phase III drug development studies and in clinics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jan
28
Featured Webinar

Implementation of a Customized Myeloid NGS-based Solution in an Academic Clinical Laboratory

Sponsored by
Sophia Genetics

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

What's Popular?

In Cancer

  1. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

  2. JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More

  3. Bionano Genomics Stock Soars on User Presentations, Public Stock Offering, Renewed Nasdaq Compliance

  4. Predictive Oncology Prices $2.2M Direct Offering

  5. OncoHost Raises $8 Million in Series B Funding Round

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.